Navigation Links
NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Date:4/29/2009

1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the size, scope and growth of potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates and its plans with regard to seeking potential development partners for its early stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret pr
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
2. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
3. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
4. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. NeurogesX Reports Third Quarter 2008 Results
6. NeurogesX to Report Third Quarter 2008 Financial Results
7. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
8. NeurogesX Responds to EMEAs Day 120 Questions
9. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
10. NeurogesX Reports Second Quarter 2008 Results
11. NeurogesX to Report Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Albany, NY (PRWEB) July 26, 2014 ... 2020 provides key market data on the Canada ... in millions of US dollars, volume (in units) ... segments - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy ... Browse Full Report at http://www.marketresearchreports.biz/analysis/213254 . , ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... OAKS, Calif. , July 25, 2014 ... Board of Directors today declared a $0.61 per share ... will be paid on Sept. 5, 2014, to all ... on Aug. 14, 2014.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
(Date:7/25/2014)... bacteria live in each person,s digestive tract. Scientists believe ... stave off harmful infections, but their role in human ... light on the role of these bacteria, a team ... recently tracked fluctuations in the bacterial populations of two ... in the July 25 issue of the journal ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... to Take Full Control of the Entire Clinical ... Disclosure - while Adhering to Changing Regulatory Requirements; ... Their Clinical Trial Registration and Results Disclosure ProcessesNEW ... http://www.intrasphere.com ), a leading services ...
... - European Operating Room Nurses Association ... Accepted,for Accreditation , Earlier today, ... has announced it has taken a further step in ... continued,education. , After receiving earlier ...
... Researchers at Eindhoven University of Technology (TU/e) have developed ... the first time they used mechanical forces to control ... in chemistry. This allowed them to initiate chemical reactions ... developing materials capable of repairing themselves under the influence ...
Cached Biology Technology:Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 2Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 4A molecular ripcord for chemical reactions 2
(Date:7/27/2014)... that nicotine and cotinine, a metabolite of nicotine, can ... in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is ... ends up in the tobacco smoke. Once inhaled, it ... is activated by a variety of enzymes called Cytochrome ... nicotine can partially interfere with the activation of NNK, ...
(Date:7/27/2014)... wiped them out if it had taken place slightly ... fresh study using up-to-date fossil records and improved analytical ... of the prehistoric creatures, demise, some 66 million years ... years before a 10km-wide asteroid struck what is now ... volcanic activity, changing sea levels and varying temperatures. ...
(Date:7/27/2014)... the largest prevalence studies to date, researchers from the ... for the hepatitis C virus (HCV). Findings published in ... Study of Liver Diseases, indicate that genotype 1 is ... infected of which one-third reside in East Asia. Genotype ... next most prevalent, followed by genotypes 2, 4, 6, ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
... to train workforce, stimulate economy ALEXANDRIA, Va., May 7 ... 2010 budget request, proposing level funding for the Carl ... at $1.3 billion. The Perkins Act is the primary ... that connect education and real-world careers. The Association for ...
... Providers Team Up to Provide High Volume Transaction ... SHORES, Calif. and NEW YORK, May 11 ... Board: CICI), a leading supplier of electronic signature ... industry* and the recognized leader** in biometric signature ...
... and BEIJING, May 20 Validus Technologies Corporation ... they have formed a strategic manufacturing, marketing and ... of One Time Password (OTP) authentication products to ... http://www.newscom.com/cgi-bin/prnh/20081104/AQTU067LOGO )With increasing data breaches, which have created ...
Cached Biology News:Obama Budget Level Funds Career Technical Education 2Obama Budget Level Funds Career Technical Education 3Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 2Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 3Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 4Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 5Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 2Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 3
... a series of media originally developed at the ... for the large scale propagation of cells from ... used for the growth and maintenance of cell ... viruses in these cell lines. One of the ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Mfr Desig: ...
Biology Products: